Epix and Mallinckrodt link with Siemens:
This article was originally published in Clinica
Siemens Medical Systems, Epix Medical and Mallinckrodt are to collaborate on developing contrast-based cardiovascular magnetic resonance imaging (MRI) technologies. The collaboration will combine AngioMark-enhanced MRI with advanced imaging and three-dimensional computerised visualisation technologies. AngioMark, Epix and Mallinckrodt's intravascular contrast agent, is currently in Phase II trials for detecting aorto-iliac occlusive disease.
You may also be interested in...
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.